Mark A. Mintun,Albert Lo,Cynthia Evans,Alette M. Wessels,Paul Ardayfio,Scott W. Andersen,Sergey Shcherbinin,JonDavid Sparks,John R. Sims,Mirosław Bryś,Liana G. Apostolova,Stephen Salloway,Daniel Skovronsky
A hallmark of Alzheimer's disease is the accumulation of amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form of deposited Aβ, is being investigated for the treatment of early Alzheimer's disease.